Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 3, 2005, Pages 559-565

  Sun, Heather K ^a   Lee, Su Young ^a   Banevicius, Mary Anne ^a   Du, Xiaoli ^a   Maglio, Dana ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Mouse model; Pulsatile dosing; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; MACROLIDE; PENICILLIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IN VIVO STUDY; LOBAR PNEUMONIA; MONOTHERAPY; MOUSE; NONHUMAN; PATIENT COMPLIANCE; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AMOXICILLIN; ANIMALS; BACTERIAL PROTEINS; CLARITHROMYCIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; MEMBRANE PROTEINS; METHYLTRANSFERASES; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, PNEUMOCOCCAL; PULSE THERAPY, DRUG; STREPTOCOCCUS PNEUMONIAE;

EID: 24644441670     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki261     Document Type: Article

References (21)

1. Felmingham D, Reinert RR, Hirakata Y et al. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002; 50 Suppl. S1: 25-37.
2. Azoulay-Dupuis E, Moine P, Bedos P et al. Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. Antimicrob Agents Chemother 1996; 40: 941-6.
3. Woodnutt G, Berry V. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43 35-40.
4. Maglio D, Capitano B, Banevicius MA et al. Efficacy of clarithromycin against Streptococcus pneumoniae expressing mef A)-mediated resistance. Int J Antimicrob Agents 2004; 23: 498-501.
5. Maglio D, Capitano B, Banevicius MA et al. Differential efficacy of clarithromycin in lung versus thigh infection models. Chemotherapy 2004; 50: 63-6.
6. Hoffman HL, Klepser ME, Ernst EJ et al. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob Agents Chemother 2003; 47: 739-46.
7. Gotfried MH, Dattani D, Riffer E et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002; 24: 736-51.
8. Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-33.
9. Heffelfinger JD, Dowell SF, Jorgensen JH et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the drug-resistant Streptococcus pneumoniae therapeutic working group. Arch Intern Med 2000; 160: 1399-1408.
10. Martinez JA, Horcajada JP, Almela M et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389-95.
11. Sun H, Maglio D, Nicolau D. Macrolide resistance in Streptococcus pneumoniae: Mechanisms, patterns, and clinical implications of resistance. Connecticut Med 2004; 68: 571-76.
12. Ibrahim KH, Gunderson BW, Hermsen ED et al. Pharmacodynamics of pulse dosing versus standard dosing: In vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron. Antimicrob Agents Chemother 2004; 48: 4195-99.
13. Cha R, Rybak MJ. Pulsatile delivery of amoxicillin against Streptococcus pneumoniae. J Antimicrob Chemother 2004; 54: 1067-71.
14. Leuthner KD, Cheung CM, Rybak MJ. Pulsatile delivery of clarithromycin alone and in combination with amoxicillin against Streptococcus pneumoniae (SPN) with reduced susceptibility to these agents. In Programs and Abstracts of the Forty-forth, Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA. Abstract A1169. American Society for Microbiology, Washington, DC, USA.
15. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests For Bacteria that Grow Aerobically - Fourteenth Edition: Approved Standard. NCCLS, Wayne, PA, USA.
16. Joly-Guillou ML, Wolff M, Pocidalo JJ et al. (1997) Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the post-antibiotic effect of imipenem. Antimicrob Agents Chemother 2004; 41: 345-51.
17. Conte JE, Golden JA, Duncan S et al. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother 1995; 39: 334-38.
18. Tessier PR, Kim M, Zhou W et al. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 2002; 46: 1425-34.
19. Amoxil [Prescribing Information]. Research Triangle Park, NC, USA: GlaxoSmith Kline; 2004.
20. Biaxin [Prescribing Information]. North Chicago, IL, USA: Abbott Laboratories; 2003.
21. Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: Findings of the PROTEKT surveillance study. Diagn Microbiol Infect Dis 2003; 45: 251-9.